Sugi Predict

Sugi Predict / Compounds / SCHEMBL10185366

SCHEMBL10185366

SCHEMBL10185366

CC(C)(C)c1cc(N)cc(C(N)=O)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DHODH Q02127 1/20 0.42
▸ EPHX2 P34913 2/20 0.39
▸ NR1H4 Q96RI1 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ RXRA P19793 3/20 0.38
▸ RXRB P28702 2/20 0.38
▸ TSHR P16473 1/20 0.38
▸ RXRG P48443 1/20 0.38
▸ LRRK2 Q5S007 1/20 0.37
▸ ESRRG P62508 1/20 0.37
▸ ACHE P22303 3/20 0.37
▸ GABRA1 P14867 1/20 0.37
▸ GABRB2 P47870 1/20 0.37
▸ MAPT P10636 3/20 0.36
▸ GAA P10253 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ HDAC3 O15379 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36
▸ HTR1D P28221 1/20 0.35
▸ HTR1B P28222 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL47585 0.87 GABRA1 (0.48) DHODHEPHX2NR1H4POLBRXRA
SCHEMBL12187779 0.84 CA5A (0.40) EPHX2NR1H4POLBRXRARXRB
SCHEMBL602656 0.84 RXRB (0.50) DHODHEPHX2NR1H4POLBRXRA
SCHEMBL6362506 0.80 RXRA (0.50) DHODHEPHX2NR1H4POLBRXRA
SCHEMBL11347527 0.80 RXRA (0.49) DHODHEPHX2NR1H4POLBRXRA
SCHEMBL4472344 0.80 CES2 (0.52) DHODHRXRARXRBTSHRRXRG
SCHEMBL14534692 0.80 DHODH (0.60) DHODHEPHX2NR1H4RXRARXRB
SCHEMBL1530343 0.79 NOTUM (0.46) POLBTSHRMAPTGAAKDM4E
SCHEMBL16106452 0.79 EPHX2 (0.44) EPHX2NR1H4ESRRGHDAC3HDAC6
SCHEMBL28490710 0.79 POLB (0.41) EPHX2POLBRXRARXRBRXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2981535-B1 UREA DERIVATIVES USEFUL AS KINASE INHIBITORS TOPIVERT PHARMA LTD (GB) 2020-12-16 — — EP disclosed
EP-3394059-B1 1-(3-TERT-BUTYL-PHENYL)-3-(4-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-6-YLOXY)-1,2,3,4-TETRAHYDRO- NAPHTHALEN-1-YL)-UREA DERIVATIVES AND THEIR USE AS P38 MAPK INHIBITORS CHIESI FARM SPA (IT) 2020-11-25 — — EP disclosed
US-10435361-B2 Kinase inhibitors TOPIVERT PHARMA LIMITED (GB) 2019-10-08 — — US disclosed
EP-3394059-A1 1-(3-TERT-BUTYL-PHENYL)-3-(4-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-6-YLOXY)-1,2,3,4-TETRAHYDRO- NAPHTHALEN-1-YL)-UREA DERIVATIVES AND THEIR USE AS P38 MAPK INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2018-10-31 — — EP disclosed
US-10100050-B2 Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2018-10-16 — — US disclosed
CN-105246884-B Urea derivative as kinase inhibitor 瑞斯比维特有限公司 2018-05-22 — — CN disclosed
US-20180044288-A1 KINASE INHIBITORS OXULAR ACQUISITIONS LIMITED (GB) 2018-02-15 — — US disclosed
US-9790174-B2 Kinase inhibitors RESPIVERT LIMITED (GB) 2017-10-17 — — US disclosed
WO-2017108737-A1 1-(3-TERT-BUTYL-PHENYL)-3-(4-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-6-YLOXY)-1,2,3,4-TETRAHYDRO- NAPHTHALEN-1-YL)-UREA DERIVATIVES AND THEIR USE AS P38 MAPK INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2017-06-29 — — WO disclosed
US-20170183345-A1 KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2017-06-29 — — US disclosed
US-20160376232-A1 KINASE INHIBITORS OXULAR ACQUISITIONS LIMITED (GB) 2016-12-29 — — US disclosed
US-9481648-B2 Kinase inhibitors RESPIVERT LIMITED (GB) 2016-11-01 — — US disclosed
EP-2981535-A1 UREA DERIVATIVES USEFUL AS KINASE INHIBITORS Respivert Limited (GB) 2016-02-10 — — EP disclosed
CN-105246884-A Urea derivatives useful as kinase inhibitors RESPIVERT LTD 2016-01-13 — — CN disclosed
US-20150166483-A1 KINASE INHIBITORS RESPIVERT LTD (GB) 2015-06-18 — — US disclosed
WO-2014162126-A1 UREA DERIVATIVES USEFUL AS KINASE INHIBITORS RESPIVERT LIMITED (GB) 2014-10-09 — — WO disclosed
US-20140296208-A1 KINASE INHIBITORS TOPIVERT PHARMA LIMITED (GB) 2014-10-02 — — US disclosed
US-20120040951-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. 2012-02-16 — — US disclosed
WO-2010078408-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS BIOGEN IDEC MA INC. (US) 2010-07-08 — — WO disclosed
WO-2008021388-A1 HETEROARYL DERIVATIVES AS CYTOKINE INHIBITORS KEMIA, INC. (US) 2008-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180044288-A1 KINASE INHIBITORS SYK, LYN, BTK DHODH 4750/4885EPHX2 3473/4885NR1H4 2186/4885
US-20120040951-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS BRAF, RAF1, ARAF DHODH 1785/4885EPHX2 1216/4885NR1H4 1008/4885
US-20160376232-A1 KINASE INHIBITORS LYN, SYK, LCK DHODH 4550/4885EPHX2 3098/4885NR1H4 2227/4885
US-10100050-B2 Kinase inhibitors MAPK1, MAP3K1, MAP3K6 DHODH 2963/4885EPHX2 2481/4885NR1H4 850/4885
US-20150166483-A1 KINASE INHIBITORS LCK, SYK, FYN DHODH 4112/4885EPHX2 2176/4885NR1H4 1571/4885
US-20170183345-A1 KINASE INHIBITORS MAPK1, MAP3K1, MAP3K6 DHODH 2963/4885EPHX2 2481/4885NR1H4 850/4885
US-10435361-B2 Kinase inhibitors SYK, LYN, BTK DHODH 4750/4885EPHX2 3473/4885NR1H4 2186/4885
US-20140296208-A1 KINASE INHIBITORS SYK, LYN, BTK DHODH 4750/4885EPHX2 3473/4885NR1H4 2186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.